Related Experiment Video
Updated: Aug 9, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
[Coma following chemotherapy: is 5FU implicated? Discussion about on case-report]
Frédéric Heluwaert1, Charles Santre, Claude Martin
1Service d'Hépato-Gastroentérologie, CH de la région d'Annecy, Annecy. fheluwaert@chu-grenoble.fr
Gastroenterologie Clinique Et Biologique
|March 28, 2006
Summary
5-Fluorouracil (5FU) chemotherapy can cause severe adverse events like coma, potentially due to hyperammoniemia. This case report details a patient who recovered from 5FU-induced coma, highlighting hyperammoniemia as a likely cause.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- 5-Fluorouracil (5FU) is a cornerstone antioncogenic and cytostatic chemotherapy agent widely used in digestive oncology.
- Severe adverse events, including encephalopathy and coma, have been associated with 5FU treatment.
- Hyperammoniemia is a potential underlying mechanism for 5FU-induced neurological toxicity.
Observation:
- A case of coma following 5FU chemotherapy in a patient with digestive cancer is presented.
- The patient experienced a coma as a severe adverse event during 5FU treatment.
- Diagnostic workup excluded other potential etiologies for the coma.
Findings:
- Hyperammoniemia was identified as a credible cause for the observed coma.
- The patient demonstrated a favorable outcome and recovery following the chemotherapy-induced coma.
- This case supports the hypothesis linking hyperammoniemia to 5FU neurotoxicity.
Implications:
- Awareness of hyperammoniemia as a potential cause of 5FU-induced coma is crucial for oncologists.
- Prompt recognition and management of hyperammoniemia may improve patient outcomes in cases of 5FU neurotoxicity.
- Further research into the mechanisms of 5FU neurotoxicity and hyperammoniemia is warranted.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...